AstraZeneca PLC (AZN)vsTherapeuticsMD Inc (TXMD)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
TXMD
TherapeuticsMD Inc
$2.04
-3.32%
HEALTHCARE · Cap: $24.31M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1943613% more annual revenue ($58.74B vs $3.02M). AZN leads profitability with a 17.4% profit margin vs -18.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TXMD
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for TXMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Revenue surging 33.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : TXMD
The strongest argument for TXMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 33.9% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : TXMD
The primary concerns for TXMD are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while TXMD is a hypergrowth play — different risk/reward profiles.
TXMD carries more volatility with a beta of 0.56 — expect wider price swings.
TXMD is growing revenue faster at 33.9% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 32/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
TherapeuticsMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?